Market closed

Ionis Pharmaceuticals/IONS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Ticker

IONS
Trading on

Industry

Biotechnology

Employees

927

IONS Metrics

BasicAdvanced
$6B
Market cap
-
P/E ratio
-$2.53
EPS
0.40
Beta
-
Dividend rate
$6B
0.4
$54.44
$35.95
2.1M
7.608
6.901
731.818
812.121
-3.68%
-7.59%
-105.71%
6.739
20.97
20.97
-14.612
29.00%
16.59%
5.75%
-13.57%

What the Analysts think about IONS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Ionis Pharmaceuticals stock.

IONS Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

IONS Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy IONS

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals (IONS) has a market cap of $6B as of October 06, 2024.

What is the P/E ratio for Ionis Pharmaceuticals stock?

The price to earnings (P/E) ratio for Ionis Pharmaceuticals (IONS) stock is 0 as of October 06, 2024.

Does Ionis Pharmaceuticals stock pay dividends?

No, Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders as of October 06, 2024.

When is the next Ionis Pharmaceuticals dividend payment date?

Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders.

What is the beta indicator for Ionis Pharmaceuticals?

Ionis Pharmaceuticals (IONS) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.